Pfizer IncPFE
▲ PositiveTechnologyrelevance
CEO plans to focus on AI transformation to accelerate drug development and improve efficiency.

Pfizer CEO Albert Bourla said the company does not expect to make any significant acquisitions in the next couple of years, instead planning to focus on transforming its businesses with artificial intelligence. Speaking on the company's most recent earnings call, Bourla stated that now is the time to execute on AI transformation without the disruption of a mega merger. He sees potential for AI to accelerate drug development, improve efficiency, and strengthen financial results. The shift follows Pfizer's $43 billion acquisition of oncology company Seagen in 2023, and comes as the stock has fallen 35% over the past five years.
Pfizer IncCEO plans to focus on AI transformation to accelerate drug development and improve efficiency.